HIV Vector Particles Targeting CD34+ Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vector particles lack specificity and efficiency in targeting CD34+ cells for gene therapy, requiring transduction adjuvants and exhibiting lower transduction rates without them, and show non-selective transduction of peripheral blood lymphocytes.
Innovation Solution
HIV-derived vector particles co-displaying the RDTR and SCF proteins, which are not dependent on RETRONECTIN for transduction, achieve efficient and specific transduction of CD34+ cells in fresh whole blood at low dosages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If vector particles display VSV-G envelope glycoprotein, then transduction rate is improved, but specificity towards CD34+ cells deteriorates
Solution Approach 1:
The patent combines two different envelope glycoproteins (RD114 and VSV-G) into a single chimeric envelope protein structure. The RD114 portion provides specificity for CD34+ cells while the VSV-G portion contributes to transduction efficiency, allowing the vector particles to achieve both high transduction rates and specific targeting of CD34+ cells simultaneously
Solution Approach 2:
The invention creates a composite envelope structure by fusing domains from two different viral glycoproteins. The chimeric envelope comprises the transmembrane and extracellular domains of RD114 fused to the cytoplasmic domain of VSV-G, creating a hybrid structure that integrates the targeting specificity of RD114 with the transduction capabilities of VSV-G
2Productivity
If transduction adjuvant RETRONECTIN is used, then transduction efficiency is improved, but process complexity deteriorates
Solution Approach 1:
The patent extracts and eliminates the dependency on external transduction adjuvants like RETRONECTIN by engineering the vector particles themselves to possess inherent transduction capabilities. The modified envelope glycoproteins enable the vectors to transduce CD34+ cells directly without requiring additional adjuvant substances or complex multi-step protocols
Solution Approach 2:
The vector particles are designed to be self-sufficient for transduction by incorporating envelope glycoproteins with both targeting and transduction functions. This self-service capability allows the vectors to efficiently transduce CD34+ cells on their own, eliminating the need for external adjuvants and simplifying the transduction process
3Adaptability or versatility
If vector particles target peripheral blood lymphocytes, then transduction breadth is improved, but targeting specificity deteriorates
Solution Approach 1:
The patent applies local quality by modifying specific regions of the envelope glycoprotein structure to confer CD34+ cell specificity. The RD114-derived transmembrane and extracellular domains provide localized binding specificity for CD34+ cell surface receptors, ensuring that transduction is concentrated on the target cell population rather than distributed across all blood cells
Data Source
AI summary
The present invention relates to a vector particle for transferring biological material into cells, wherein said vector particle comprises at least:a first protein which comprises the transmembrane and extracellular domains of the feline endogenous RD114 virus envelope glycoprotein, anda second protein which comprises a ligand of the c-Kit receptor.